The ameliorative effect of Lactobacillus plantarum Y44 oral administration on inflammation and lipid metabolism in obese mice fed by high fat diet
In our previous studies, Lactobacillus. plantarum Y44 showed antioxidant activity and favorable gastric and intestinal transit tolerance. The purpose of this study is to determine whether L. plantarumY44 could ameliorate intestinal inflammation and lipid metabolism disorder in obese mice fed by high-fat diet. L. plantarumY44 was gavage administrated to the mice fed by high-fat diet for 12 weeks. The mice fed by high fat diet only showed the sustainably elevated body weight, liver lipid metabolism disorder, intestinal inflammation and lower short chain fatty acid in feces. Oral administration of L. plantarumY44 regulated lipid metabolism disorder by inhibiting the expression of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) in liver of obese mice, reducing the contents of total cholesterol (TC), triacylglycerols (TG), low density lipoprotein cholesterol (LDL-c), alanine aminotransferase (ALT), aspartate transaminase (AST) and increasing the content of high-density lipoprotein cholesterol (HDL-c) in serum of obese mice. Oral administration of L. plantarumY44 up-regulated the expression of colon tight junction protein such as claudin-1 and occludin, down-regulated p38 and phospho-p38 levels and reduced serum interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α). Oral administration of L. plantarum Y44 increased Muribaculaceae, Rikenellaceae, Lactobacillaceae levels, reduced the Firmicutes/Bacteroidetes ratio, Desulfovibrionaceae and Proteobacteria levels in obese mice. Oral administration of L. plantarumY44 also enhanced the contents of propionic acid, butyric acid, butanoicacid-3-methyl, pentanoic acid and acetic acid in the feces of the obese mice. Correlation analysis of Spearman revealed a significant correlation between changes in intestinal microflora and obesity-related symptoms. L. plantarumY44 ameliorated intestinal inflammation and lipid metabolism disorders by modulating gut microbiota.